Filing Flows › Sonoma Pharmaceuticals (SNOA) › Who owns the stock
Who owns Sonoma Pharmaceuticals (SNOA) stock
13 funds reported Sonoma Pharmaceuticals (SNOA) shares in their latest 13F filings, worth $205K in all. The largest holder is Vanguard Group ($69K). Last quarter 4 funds added to their stakes and 6 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 18,887 | $69K | decrease | 2025-12-31 |
| Renaissance Technologies LLC | 40,468 | $50K | new | 2026-06-30 |
| Geode Capital Management, LLC | 26,787 | $33K | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 18,787 | $23K | unchanged | 2026-06-30 |
| McKinley Carter Wealth Services | 11,193 | $14K | unchanged | 2026-09-30 |
| UBS Group AG | 7,808 | $10K | increase | 2026-06-30 |
| Global Retirement Partners, LLC | 2,548 | $3K | increase | 2026-06-30 |
| Morgan Stanley | 2,000 | $2K | decrease | 2026-06-30 |
| Osaic Holdings | 500 | $1K | unchanged | 2026-06-30 |
| BlackRock | 113 | $139 | unchanged | 2026-06-30 |
| Vanguard Fiduciary Trust | 100 | $123 | unchanged | 2026-06-30 |
| CWM, LLC | 1 | $2 | unchanged | 2026-03-31 |
| Danske Bank A/S | 1 | $1 | unchanged | 2026-06-30 |
Sonoma Pharmaceuticals' latest quarter
Sonoma Pharmaceuticals, Q1 FY27: revenue $6.4M (+60% year over year), operating margin -0.6%, net loss $330K, operating cash flow −$649K. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most SNOA stock?
By the latest 13F filings: Vanguard Group ($69K); Renaissance Technologies LLC ($50K); Geode Capital Management, LLC ($33K); Vanguard Capital Management LLC ($23K); McKinley Carter Wealth Services ($14K).
What is the short interest in SNOA?
108,814 shares were sold short at the 2026-10-15 settlement, -33.85% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.